As member states of the United Nations take stock of the drug control system, a number of debates have emerged among governments about how to balance international drug laws with human rights, public health, alternatives to incarceration, and experimentation with regulation.

This series intends to provide a primer on why governments must not turn a blind eye to pressing human rights and public health impacts of current drug policies.
WHAT IS HARM REDUCTION?

Harm reduction is based on the idea that people have the right to be safe and supported even if they are not ready or willing to abstain from illicit drug use. A harm reduction approach involves giving people who use drugs choices that can help them protect their health.

An example of a harm reduction approach is providing people who inject drugs with access to sterile injection equipment, which reduces the risk of HIV and hepatitis C transmission. Treatment with the oral medications methadone and buprenorphine, given under medical supervision, reduces overdose and injection of heroin and other opiates. While harm reduction often focuses on addressing health harms, the term is also used to describe measures that reduce the adverse consequences of drug law enforcement, such as training of police to increase diversion of people who use drugs to health services.
Harm reduction approaches are important for addressing many public health and social problems. To combat driving under the influence of alcohol, for example, societies do not ban driving or prohibit drinking. They may institute harm reduction measures such as encouraging social groups to designate non-drinking drivers, or providing free or subsidized transportation for people who have been drinking.

Drug-related harm reduction takes a similar approach, emphasizing measures to reduce risk rather than demanding total abstinence. While harm reduction approaches often serve as a bridge to drug dependence treatment or cessation of drug use, these outcomes are not preconditions or the only goals. Harm reduction programs may include measures such as drug consumption rooms where people can consume drugs under medical supervision; heroin prescription and supervised administration; and distribution of the medicine naloxone to people who use opioids and their families, police, and emergency medical teams for use in reversing fatal overdose. Some municipal housing programs also take a harm reduction approach, for example, offering shelter without requiring residents to cease use of crack or other illicit substances in order to mitigate the high risk of chronic homelessness and its concomitant health-related and social harms.

“While harm reduction approaches often serve as a bridge to drug dependence treatment or cessation of drug use, these outcomes are not preconditions or the only goals.”
WHAT DOES THE UNITED NATIONS SAY ABOUT HARM REDUCTION?

Harm reduction emerged as a guiding principle for health programs after two of the UN drug conventions—those of 1961 and 1971—were written and came into force. The 1988 convention, while mentioning the importance of improving health, does not mention harm reduction. Nonetheless, the UN has affirmed harm reduction in multiple settings and declarations.

The unanimous 2001 Declaration of Commitment on HIV/AIDS was the first major statement of all United Nations member states on drug-related harm reduction. In the declaration, member states committed themselves to ensuring implementation of a “wide range of [HIV] prevention programmes,” notably “expanded access to essential commodities, including…sterile injecting equipment [and] harm-reduction efforts related to drug use…”1 The commitment of UN member states to harm reduction as a mainstay of HIV prevention was reiterated in the 2006 General Assembly Political Declaration on HIV/AIDS.2

Several documents published by the Joint United Nations Programme on HIV/AIDS (UNAIDS) have since reiterated the importance of harm reduction in national and global HIV responses. As noted in the 2014 UNAIDS publication Harm Reduction Works:

“Abundant evidence shows that harm reduction programs can significantly reduce HIV


transmission among people who inject drugs…. Countries should not wait, but should start immediately to scale up harm reduction responses that are public health-based and human rights informed.³

In 2004, the World Health Organization (WHO), the UN Office on Drugs and Crime (UNODC), and UNAIDS issued a position paper asserting the importance of medically assisted treatment of opioid dependence using methadone or buprenorphine.⁴ As stated in this paper:

As with other health conditions such as hypertension, diabetes and heart disease, people with opioid dependence can stabilize their condition by developing and incorporating behavioral changes and by appropriate use of medicines….The ultimate achievement of a drug-free state…is unfortunately not feasible for all individuals with opioid dependence, especially in the short term. An exclusive focus on achieving a drug-free state for all patients may jeopardize the achievement of other important objectives, such as HIV prevention.⁵

The 2006 International Guidelines on HIV/AIDS and Human Rights published by UNAIDS and the Office of the High Commissioner for Human Rights underscored the importance of an enabling legal environment for harm reduction measures. It enjoined countries, for example, to review their criminal law with an eye to ensuring that the law does not impede “authorization… and promotion of needle and syringe programmes” and especially does not criminalize “the possession, distribution and dispensing of needles and syringes.”⁶ The Guidelines underscore the human rights responsibility of governments to take necessary measures to ensure HIV services for people who use drugs and other populations that “already suffer from a lack of human rights protection and from discrimination and/or are marginalized by their legal status.”⁷

---


⁵ Ibid. p 8.


⁷ Ibid. p 78.
UN legal experts on the drug conventions have concluded that needle and syringe programs, methadone and buprenorphine treatment, and supervised drug consumption rooms are consistent with the spirit of the conventions. With respect to supervised drug consumption rooms, for example, the UN’s in-house legal experts noted that the intent of these facilities is not to induce drug use but rather “to provide healthier conditions” for people who inject drugs, “reducing their risk of infection with grave transmittable diseases and, at least in some cases, reaching out to them with counseling and other therapeutic options.”

WHO, UNODC and UNAIDS have repeatedly affirmed the importance of harm reduction, including in prisons. WHO’s 2014 guidelines on services for “key populations” affected by HIV emphasize that drug-related harm reduction should be a policy and program priority, and stress the need for programs to be protected from undue police surveillance or other interference. As the former executive director of UNODC noted in 2007: “Harm reduction is often made an unnecessarily controversial issue as if there [were] a contradiction between prevention and treatment on one hand and reducing the adverse health and social consequences of drug use on the other. This is a false dichotomy. They are complementary.”

8 International Narcotics Control Board. Flexibility of treaty provisions as regards harm reduction approaches [decision 74/10, prepared by the UN Drug Control Programme Legal Affairs Section]. UN doc. no. E/INCB/2002/W.13/SS.5, 30 September 2002.


“An exclusive focus on achieving a drug-free state for all patients may jeopardize the achievement of other important objectives, such as HIV prevention.” – WHO, UNODC and UNAIDS, 2004
EVIDENCE FROM RESEARCH AND NATIONAL PRACTICE

UN agencies have also reviewed the scientific evidence of harm reduction measures. An extensive review of needle and syringe programs (NSP) commissioned by WHO, for example, documented the many peer-reviewed studies showing that NSP reduced risk of HIV.\(^\text{12}\) It also concluded that there was no evidence that NSP led to new or increased drug use or that NSP contributed to crime. Rather, needle and syringe programs were found not only to reduce HIV transmission but also to contribute to safe disposal of syringes and referrals to treatment and other care for people who inject drugs.\(^\text{13}\)

Treatment with buprenorphine or methadone, also called opioid substitution treatment or maintenance therapy for opiate dependence, is endorsed as an important part of HIV national responses by WHO, UNODC, and UNAIDS\(^\text{14}\) and has been the subject of scholarly research for decades. Many randomized controlled studies, meta-analyses, and systematic reviews have demonstrated the effectiveness of these medicines both in treating opioid dependence and in reducing the harms of drug injection, including HIV transmission.\(^\text{15}\) Treatment with methadone and buprenorphine has also been associated with improved family function and employment, reduced criminal activity, and increased self-efficacy.\(^\text{16}\)

Medically supervised facilities where people inject or smoke drugs have also demonstrated positive health impact. Studies of Insite, the supervised injection facility in Vancouver, Canada, have contributed a large body of peer-reviewed research to scholarship in this area. Insite’s work has been shown to be associated with, among


\(^{13}\) Ibid. See also WHO Consolidated guidelines ...for key populations, op.cit.

\(^{14}\) WHO, UNODC, UNAIDS, op.cit. (note 4).


\(^{16}\) WHO, UNODC, UNAIDS, op.cit.
other things, reduced HIV transmission, prevention of death from overdose, reduced needle sharing, improved public order and reduced crime in the neighborhood of the facility, reduced injection-related injury and infection, and improved referral to drug dependence treatment and other health services for people who use drugs. These benefits have been achieved without increase in new drug use and with significant cost savings for the public health budget of the city and province.\textsuperscript{17} Some of the same effects have been demonstrated in supervised injection facilities in Australia,\textsuperscript{18} as well as in several countries in western Europe.\textsuperscript{19}

The strong evidence of positive effects of harm reduction measures has informed and inspired drug policy change in a number of countries, including the following:

**Switzerland**

Faced with a very fast-growing injection-linked HIV epidemic in the late 1980s, the Swiss government instituted low-threshold methadone treatment and NSP in virtually all cities and established supervised drug consumption sites in bigger cities.\textsuperscript{20} HIV transmission linked to drug use plummeted and has remained very low.\textsuperscript{21} Switzerland coined the term “four pillars” to describe its drug policy, which is based on policing (supply reduction), demand reduction, harm reduction, and prevention of drug use.\textsuperscript{22} This framework has been adopted in many countries.

**Portugal**

In the 1980s and 1990s, Portugal faced rapidly escalating HIV linked to growing drug consumption following its long period as a dictatorship. In 2001, the government instituted many of the same harm reduction and drug dependence treatment measures as in Switzerland but with the additional reform of removing drug consumption and minor possession offenses from its criminal law. Injection-linked HIV and problematic drug use have both declined dramatically.\textsuperscript{23}

\textsuperscript{17} See summary in Urban Health Research Initiative, University of British Columbia. Insight into Insite. Vancouver, undated. At: http://uhri.cfenet.ubc.ca/content/view/57/92/


\textsuperscript{22} Csete and Grob, op.cit.

Vietnam

Facing high HIV incidence and prevalence among people who inject drugs, the government of Vietnam in 2006 passed an HIV law that explicitly adopted harm reduction measures—including provision of condoms, sterile needles, and syringes, as well as opiate substitution therapy—as central to the national HIV response. NSP and methadone treatment have expanded significantly in recent years. One program that supported peer-based outreach and provision of injection equipment near the border with China found substantial reductions in needle-sharing, HIV incidence, and HIV prevalence over an eight-year period, representing an enormous saving in cost and disease burden as well as potentially lasting behavior change. As methadone has expanded, Vietnam has also taken steps to reduce its reliance on compulsory drug detention centers, which were created purportedly for rehabilitation but have offered few services beyond physical discipline and forced labor.

“A World Bank study indicated that harm reduction services in Malaysia averted over 13,000 cases of HIV in the period 2005–2013 and projected that over 100,000 infections may be averted by the year 2050.”

Iran

Harm reduction measures are protected in Iran by a 2005 order from the head of the national judiciary, which instructed criminal justice and law enforcement agents not to interfere with NSP or methadone-assisted treatment services as these were essential for protection of the population from infectious disease. The order gave explicit protection from criminal prosecution to health workers providing harm reduction services. Iran also established methadone maintenance treatment in prisons, recognizing that many people entered prison or pretrial detention with opiate dependence. From 2004 to 2014, the number of methadone patients went from a few hundred

27 Ibid.
to over 41,000 in 164 prisons and detention centers with a concomitant threefold reduction in HIV incidence. Iranian authorities report that, in addition to a significant contribution to HIV control, the methadone program in prisons has resulted in less violence and self-injury, less suicide, fewer abscesses and injection-related injuries, and less trafficking and use of illicit drugs in prison.29

**Malaysia**

Prior to 2005, when needle exchange and methadone treatment were put in place, drug injection was linked to a high percentage of HIV transmission in Malaysia.30 Malaysia also routinely detained people who use drugs in compulsory drug detention centers with locked facilities, where detainees were subjected to harsh punishment and emotional abuse for around two years.31 In addition to support for needle exchange and methadone, the Malaysian government began in 2010 to expand treatment in “cure and care” centers, which offer voluntary in- and out patient methadone and other health and counseling services, with the idea of reducing reliance on compulsory detention centers.32 Evaluators and representatives of the National Antidrugs Agency report that “cure and care” patients experience sharp decreases in drug injection and higher appreciation of services, sharply lowering rates of return to illicit drug use as compared to those in compulsory centers.33 Voluntary centers also cost the state more than 40 percent less per patient per year.34 More generally, a World Bank study indicated that harm reduction services in Malaysia averted over 13,000 cases of HIV in the period 2005-2013 and projected that over 100,000 infections may be averted by the year 2050.35

**China**

Tracking HIV through a nationwide sentinel surveillance system, China detected a significant HIV epidemic linked to injection of opiates by the late 1990s.36 Methadone maintenance therapy was scaled up rapidly from eight facilities in 2004 to over 700 clinics serving over 340,000 patients around the country in 2011.37 Some 91 needle exchange pilot sites opened in 2003 expanded to over 930 exchange points by 2011.38 Though the
drug injection-related HIV epidemic in China is far from over, national surveys have associated this period of expansion of harm reduction services with declining risk behaviors, including needle sharing, and declining HIV incidence from drug injection. A number of rigorous studies have shown that in addition to their HIV impact, methadone programs in China are also associated with crime reduction in affected communities, higher rates of employment among patients, and greater participation of patients in community and family activities.

REACHING THOSE IN NEED: CONTRAST WITH ABSTINENCE-BASED APPROACHES

WHO/UNODC guidance for treatment of drug dependence emphasizes the need for low-threshold options to maximize the reach of services to people who may fear or be unready for treatment. As depicted in Fig. 1, studies by governments considering inclusion of a harm reduction approach have indicated that without such low-threshold services, including harm reduction services, the large majority of people who inject drugs would simply not be reached.

Good-quality harm reduction services meet people who use drugs “where they are” and work to ensure that they have the capacity to protect themselves from the worst harms of whatever their degree of drug dependence or pattern of use. These lower-threshold services are a gate to drug dependence treatment and other health services for individuals who have remained out of reach of or resistant to higher-threshold approaches. In São Paulo, Brazil, for example, the “Open Arms” (Braços Abertos) program offers housing and employment to residents without requiring that they abstain from crack use. Hundreds of formerly homeless, street-involved individuals are now housed and employed. In Vancouver, the supervised injection site serves as a gate to the possibility of seeking other services, including treatment for drug dependence.
Fig. 1: Street-level outreach and low-threshold services reach more people than those requiring abstinence as a condition of entry.

Source: D MacPherson\(^\text{45}\)
FAILURE TO FUND HARM REDUCTION SERVICES

In spite of overwhelming scientific evidence of the success and cost-effectiveness of harm reduction measures in addressing HIV and other negative effects of drug use, harm reduction funding lags far behind need. Of the package of services proven effective in averting HIV transmission among people who use drugs, UNAIDS estimates that only seven percent are funded.46

International donors and national governments need to pledge financial commitment or harm reduction services. People who inject drugs in middle-income countries in Eastern Europe and Asia have been particularly hard hit by the Global Fund’s reduction of support to these countries.47 Countries that have been deemed too wealthy for HIV assistance from the Global Fund, such as Romania, have shown how quickly HIV epidemics among people who inject drugs can become resurgent, with infections spiking quickly after cuts to needle and syringe programs.48 Similarly, where government support for harm reduction is reduced due to budget cutbacks, as in Greece after the recession of 2008-09, HIV infection via contaminated injecting equipment often sharply increases, creating a public health problem many times more costly than harm reduction services (see Fig. 2).

Harm reduction services are cost-effective and affordable. Advocates estimate that only 10 percent of the approximately $100 billion spent annually on drug enforcement around the world would cover HIV prevention services for people who use drugs for four years.49 A widely cited study by the government of Australia concluded that for every $1 invested in NSP, over $4 would accrue in short-term health-care cost savings, and that this figure would only grow with the cumulative effect of HIV transmission averted.50

47 Ibid.
49 Cook et al, op.cit.
HARM REDUCTION

Fig. 2: Surge in HIV transmission among people who inject drugs (PWID) in Greece following cut to harm reduction services during fiscal crisis

Source: Paraskevis et al.\textsuperscript{52}
“In the UK, police have been trained not to use possession of syringes as evidence of a crime, and they even may provide sterile injecting equipment to people who have been in police custody.”

A mathematical model evaluating naloxone administration by lay witnesses—making what the authors consider to be conservative assumptions about age distribution of overdose, treatment seeking, and relapse—found that one quality-adjusted life year (QALY) resulted from $438 in program costs in the United States and $1,987 in Russia. The authors note that this is equivalent to some of the most cost-effective and accepted health interventions, such as measurement of blood pressure, and that an incremental cost of less than $50,000 per QALY gained is considered cost-effective by health policymakers.

HARM REDUCTION IN LAW ENFORCEMENT

In a number of countries, public health services have worked with law enforcement and justice system to reduce drug-related harms in various ways:

Facilitating access to services
Police in various countries have worked to ensure that harm reduction services operate without interference from law enforcement, and in some countries have facilitated access to harm reduction services. In the UK, police have been trained not to use possession of syringes as evidence of a crime, and they even may provide sterile injecting equipment to people who have been in police custody. In parts of the Netherlands, Australia, Ukraine, and Indonesia, police allow NGO representatives to bring methadone


54 Coffin and Sullivan, Annals of Internal Medicine, ibid.

treatment to patients in police lock-up or pre-trial detention.\textsuperscript{56} In several countries, police may allow outreach workers from health services to be present in police stations or otherwise to assist in ensuring that people have access to services to keep themselves safe while they are in custody.\textsuperscript{57}

The time and resources of drug police are poorly used if they are focused on people who consume, possess or sell drugs on a small scale, rather than on the most harmful elements of drug markets and drug-related crime.\textsuperscript{58} Blanket zero-tolerance approaches or use of arrest quotas to assess police performance is poor practice, and likely to result in filling prisons with minor, non-violent offenders. Police actions themselves can add to or reduce drug-related harms, causing hurried injection and injection in remote places far from services or emergency help, and may even lead people to inject rather than smoke or inhale drugs.\textsuperscript{59}

In the U.S., experiments with another approach are underway in Seattle, Washington, and Santa Fe, New Mexico, through a program called Law Enforcement Assisted Diversion (LEAD). In these initiatives, police encountering low-level, non-violent drug offenders can direct them to a range of community services and supports rather than to prosecution and jail.\textsuperscript{60} Success in the LEAD program is not judged by drug testing, but by participation and progress in programming as deemed by health and social workers. In Seattle, evaluation of the first five years of the program found that the participants diverted to services had a 58 percent lower chance of subsequent arrest compared to other drug offenders.\textsuperscript{61}

Police in some countries themselves provide a harm reduction service by using naloxone, a medicine that reverses potentially fatal opioid overdose.”
“The U.S. states are promoting Good Samaritan laws as part of expanding naloxone capacity.”

potentially fatal opioid overdose. Naloxone in injectable and nasal spray forms has been a tool for emergency medical workers in a number of countries for some time, but police are often first on the scene and can save lives. The 2014 U.S. national drug strategy, for example, states that “naloxone…should be in the patrol cars of every law enforcement professional across the nation...”62 Hand in hand with training and equipping police for overdose interventions in the U.S. is the passage of so-called “Good Samaritan” laws that protect volunteers who provide emergency services such as overdose reversal from prosecution or litigation. These laws have existed for some time in Europe,63 and U.S. states are promoting Good Samaritan laws as part of expanding naloxone capacity.64 In 2013, police in Kyrgyzstan launched an initiative to enable officers to administer naloxone for overdose.65

Reducing harms of law itself

To keep the police focused on the most damaging crimes, minor infractions should be decriminalized or effectively decriminalized through formal provision of alternatives to arrest and detention. For non-violent minor possession or sale offenses, for example, a number of countries in Europe have defined cut-off amounts of drugs below which there is no arrest but rather a fine or community service sanction.

64 Executive Office of the President, op.cit., p 3.
CONCLUSION

For many people who use drugs, harm reduction services are the most likely entry point into health care and the most likely means of protection from life-threatening conditions. As United Nations agencies have noted, the effectiveness of harm reduction services for HIV prevention and prevention of drug-related mortality is beyond dispute.

The UN General Assembly Special Session on drugs is an opportunity to re-energize the commitment to harm reduction pledged by UN member states at the 2001 UNGASS on HIV/AIDS. Funding for proven and cost-effective harm reduction services that protect not only people who use drugs but entire communities should be a top priority. Harm reduction is a central pillar of effective drug response, critical to reaching people who use drugs with services that can help protect them, their families and their communities.